Company Filing History:
2 out of 8 
2 out of 16 
1 out of 11 
Years Active: 2014-2016
Title: Lucinda Jane Goodricke Robertson: Innovator in Cysteine Protease Inhibitors
Introduction
Lucinda Jane Goodricke Robertson is a notable inventor based in Canterbury, New Zealand. She has made significant contributions to the field of biochemistry, particularly in the development of macrocyclic compounds that serve as cysteine protease inhibitors. With a total of 2 patents to her name, her work has implications for treating diseases associated with cysteine protease activity.
Latest Patents
Her latest patents include innovative methods and compositions related to macrocyclic cysteine protease inhibitors. The inventions provide a novel class of macrocyclic compounds that are useful as cysteine protease inhibitors. Additionally, they include novel intermediates and methods for preparing these compounds. The pharmaceutical compositions derived from these compounds are aimed at treating or preventing diseases linked to cysteine protease activity, particularly those associated with calpain activity.
Career Highlights
Throughout her career, Lucinda has worked with esteemed organizations such as Lincoln University and Douglas Pharmaceuticals Limited. Her research and development efforts have contributed to advancements in pharmaceutical sciences, particularly in the area of protease inhibition.
Collaborations
Lucinda has collaborated with notable colleagues, including Andrew David Abell and James Morriss Coxon. These partnerships have further enriched her research endeavors and have led to significant advancements in her field.
Conclusion
Lucinda Jane Goodricke Robertson stands out as an influential inventor in the realm of cysteine protease inhibitors. Her innovative work continues to pave the way for new therapeutic approaches in medicine.